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Background: The use of PSA for the diagnosis of cancer prostate has remained 
controversial as well as unreliable because many factors affect PSA levels. Included 
amongst the many factors that can increase PSA level are riding bicycle, rectal exam, sex, 
age, serum calcium, prostate inflammation, increased prostate volume. This study was 
aimed at determining the clinic-patho-radiological finding of patients presenting with 
enlarged prostate and to determine the PSA profile of all patients presenting with enlarged 
prostate in St. Mary’s Hospital Lacor.  
Results: Approximate 135 patients were evaluated in the study and significantly, elderly 
persons constituted 64.5%, compared with Adult (34.5%) and youth 1%, (P=0.00). Most 
patients presented with retention of urine (30%), dribbling of urine (23%), hesitancy 
(16%) and dysuria (13%). When the serum PSA was classified into Low (0.1-2.4ng/ml), 
Moderate (2.5-3.9ng/ml) and High 4ng/ml and above, we found that 60.7% of the patients 
had high PSA while 9.6% had moderate and low was 29.6%. PSA correlates positively with 
patients age (r= 0.24, P=0.005). Prostates volume also correlates positively with serum PSA, 
(Pearson’s Correlation r=0.275 and P= 0.002). Age and prostate volume also had a 
significant relation P=0.054 but there was only a very weak relationship between PSA level 
and Histological diagnosis, (Pearson’s correlation r=0.1).  
Conclusion: Age and prostate volume significantly correlate with serum PSA,  just as age 
and prostate volume also correlates significantly. 
Key words: Prostatic specific antigen (PSA), volume, age, histology.  
 
Introduction 
The incidence of prostate cancer varies widely between countries and ethnic groups. Whereas 
native Japanese have the lowest incidence, Black-Americans have the highest rates worldwide1. 
Indeed, prostate cancer is the most commonly diagnosed non–skin cancer and the second 
leading cause of cancer death in the USA with approximately 241,740 American men diagnosed 
with the disease in 2012 alone of which 28,170 of them died2. Furthermore, the incidence of 
prostate cancer in the United States and certain western countries has risen sharply during the 
last decade and the increase is more pronounced in the United States, Canada, Australia, France 
and the Asian countries3.  
However, the reported incidence of cancer prostate in Asia is much lower than that in African 
Americans and European Caucasians, and there is somewhat better prognosis in Asian 
immigrants who develop prostate cancer in the United States4.It is postulated that Soy food 
consumption is associated with a 25% to 30% reduced risk of prostate cancer in Asian4. In their 
study, Bjarne, Synnøve, Knutsen, and Gary5in 1998 also reported that men with high 
consumption of soy beans had reduced risk of prostate cancer. 
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In developing countries prostate cancer may be less common, however its incidence and 
mortality has been on the rise2.  This may be attributed to lack of dedicated efforts to search for 
the cancer. In fact cancer prostate incidence is influenced by the intensity of diagnostic efforts, 
mortality reports and active prostate specific antigen (PSA) screening4. Even when treated with 
radical prostatectomy the high PSA relapse rate signifies early metastasis even at low tumor 
volume6. Prostate-specific antigen (PSA) is the only established and routinely implemented 
clinical biomarker for prostate cancer detection and disease status2.  The introduction of total 
prostate specific antigen (total PSA) testing in blood has revolutionized the detection and 
management of men with prostate cancer because Men who will eventually develop Prostate 
cancer have increased total PSA levels years or decades before the cancer is diagnosed. 
However, PSA has limited value for Prostate Cancer screening and prognostication7. 
Prostate cancer screening using PSA has been controversial, as no studies have proven that this 
strategy reduces mortality from prostate cancer. There is also no cutoff point of PSA with 
simultaneous high sensitivity and high specificity for detecting prostate cancer, hence PSA may 
be unrelaible8.  Serum PSA measurements show variable reliability when it comes to diagnosis of 
Prostate cancer, given the dynamics of PSA physiology9. In general, prostate biopsy has not been 
recommended unless PSA levels exceed a threshold value of 4.0 ng/mL, with slightly lower 
values recommended recently by some authors. Indeed 15% of men with a PSA value less than 
4.0 ng/mL have prostate cancer and 15% of these cancers are high grade8. Even when changes 
in prostate-specific antigen (PSA) over time (PSA velocity) aid prostate cancer detection, there 
is little justification for formal calculation of PSA velocity if PSA level is ≥3 ng/ml for cut points 
to determine biopsy in men10. 
The use Prostate-specific antigen (PSA) level typically results in over diagnosis of cancer 
prostate for a substantial number of men11. This is because many factors affect PSA levels. 
Cycling causes an average 9.5% increase in PSA, when measured within 5 minutes post 
cycling11.  In addition in men over 40years a positive PSA screening result is significantly 
associated with increased age, marital status (married), higher socioeconomic status like higher 
educational attainment, and health care access12,18. Serum calcium and serum parathyroid 
hormone (PTH) stimulate prostate growth in men without clinical prostate cancer and have 
implications of increasing PSA level13. There is also a tendency of correlation between the 
presence of inflammatory prostatitis with an elevation of PSA14 and according to Dong et a115, 
significant relationship also exists between PSA and Prostate volume. Hence use of PSA as a 
screening tool for prostate cancer leaves a lot to be desired. 
There remain gross disparities between the prostate cancer risk and a given PSA level thus 
posing challenges to the use of PSA-driven algorithms to determine whether biopsy to rule out 
prostate cancer is indicated or not16. Prostate-specific antigen (PSA) lacks both sensitivity and 
specificity as a serum tumor marker in diagnosis and screening of prostate adenocarcinoma8. Its 
role in diagnosis of active prostate cancer has also remained controversial, yet it is the most 
prevalently used marker for prostate cancer, hence the need to evaluate other factors that affect 
serum PSA beside cancer prostate. The main objectives of this study were To determine the 
clinic-patho-radiological findings and the PSA profile of all patients present with enlarged 
prostate at St. Mary’s Hospital Lacor in Uganda 
Patients and Methods 
A descriptive study was done on all males patients presenting at the St Mary’ hospital Lacor 
surgical unit between Jan 2012 to Dec 2013 with enlargement of the prostate. St. Mary’s 
hospital Lacor is a rural based 483 bed hospital located in Northern Uganda and is also a 
teaching hospital for Gulu University medical school. In the 2 years (2012-2013), all patients  
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with suspected prostatic enlargement had their main clinical presentation appraised and Digital 
Rectal Exam done. They also had ultrasonography of the pelvis to assess their prostate volume 
and they were sent to the laboratory to remove sample for Prostatic specific Antigen (PSA) test 
prior to being sent for a side room procedure of tru-cut biopsy prostate. No cut off PSA was 
used; hence every one with enlarged prostate had a biopsy. At least 3 cylindrical samples were 
obtained at biopsy with a 16 gauge tru-cut gun. The histology samples were analyzed by a 
pathologist who was blinded but had to diagnose Adenocarcinoma (cancer prostate), Benign 
Prostatic Hypertrophy (BPH), Prostatitis or Normal tissue. Patient whose sample was 
insufficient to make histological diagnosis had a repeat tru-cut and those who never did PSA 
were expunged from the data set for analysis.  
The patient’s biographic data, main presenting symptom, clinical diagnosis, prostate volume, 
serum PSA level and histological findings were collected, coded, entered and analyzed using 
SPSS. 
Results 
Approximate 135 patients were evaluated in the study. The youngest person was 33years and 
the oldest was 98 years, Mean age 68.5year (SD+/- 13years). Significantly, elderly persons 
constituted 64.5%, compared with Adult who made up to 34.5% and approximately 1% was a 
youth (P=0.00) (Figure 1). The high proportion of elderly persons in this study is because as one 
ages, the prostate also tend to enlarge as a result of decrease in androgen hormone level. 
Prostate volume often increases with age17.  
 
Presenting symptoms 
Most patients presented with retention of urine (30%), dribbling of urine (23%), hesitancy 
(16%) and dysuria (13%) and this observed difference was significant P=0.00 (Table 1). On 
examination, 80% of the patients had clinical evidence of BPH and cancer prostate was 13%.  
Figure  1. Age Distribution 
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(P=0.00). However, of the patient who were clinically diagnosed with BPH, 46% correlated well 
with the histological finding While for those diagnosed with clinical caner prostate, 72% were 
found to have a positive histology findings, (P= 0.04). Therefore clinical evaluation is 
emphasized and complementary to PSA marker. 
Table 1  Presenting Main symptom            
 Symptom Frequency Percent (%) 
Urinary retention 40 29.6 
Dysuria 18 13.3 
Dribbling of urine 31 23.0 
straining to pass urine 9 6.7 
Difficulty passing urine 22 16.3 
Frequency 6 4.4 
Others 6 4.4 
Hematuria 2 1.5 
Metastasis 1 .7 
Total 135 100.0 
 
PSA Analysis. 
Of the 135 patients enrolled in the study, the serum PSA ranged from 0.1ng/ml to 88.7ng/ml 
with average of 15.6ng/ml. When the serum PSA was classified into Low (0.1-2.4ng/ml), 
Moderate (2.5-3.9ng/ml) and High 4ng/ml and above, we found the 60.7% of the patients had 
high PSA while 9.6% had moderate and low was 29.6%, (P value=0.00). Therefore when PSA is 
taken for all patients with enlarged prostate, a significant proportion of patients tend to have a 
high PSA P=0.000 (Fig 2).  
 
 
Fig ure 2. Serum PSA 
Levels 
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Prostate Histology  
Histological examination of prostate biopsy revealed BPH (39%), Cancer prostate (33%), 
inflamed prostate (15%) and intraepithelial neoplasms (12%). These observed difference in 
histology finding is significant (P=0.00), (Table 2 below). Therefore a great proportion of those 
patients who presented with enlargement of the prostate had cancer prostate, hence the need to 
biopsy all the enlarged prostates.  
 
Table 2             Histology findings 
 
 Frequency % 
 Valid BPH 53 39.3 
 Adenocarcinoma 44 32.6 
 Prostatitis 20 14.8 
 PIN 1 11 8.1 
 PIN 2 1 .7 
 PIN 3 3 2.2 
 Normal 1 .7 
 Total 133 98.5 
Missing Bad sample 2 1.5 
Total 135 100.0 
 
 
Relationship between PSA, Prostate volume, Age, and Histology (Correlations) 
As shown in table 3 below and using Figure 2, PSA correlates positively with patients age (r= 
0.24, P=0.005). Therefore as age advances, PSA also tends to increase.  Hence elderly persons 
(more than 65years old) presenting with enlarged prostate should have a tru-cut biopsy of 
prostate irrespective of the PSA level.  
In this study, prostate volume ranged from 18 to 236 mls with mean prostate volume was 
78.8mls (SD+/-41mls). Prostates volume correlates positively with serum PSA, Pearson’s 
Correlation r=0.275 and P= 0.002.Therefore as prostate volumes increases, PSA also increases.  
Furthermore prostate volume also correlates positively with increasing age (Pearson’s 
correlation r= 0.176 and P= 0.054 (table 3). There is a weak relationship between PSA level and 
Histological diagnosis, (Pearson’s correlation r=0.1, Table 3).  
As shown in Table 4,of all the patients whose PSA ranged within the low prostate cancer 
detection levels of 0-2.4ng/dl, 54% had BPH and 15.4% were found to be having cancer 
prostate.Of those whose PSA was considered high (≥4ng/dl), 32% had BPH and 42% had cancer 
prostate. This finding was not statistically significant Chi square 13.561, P= 0.33.  
As shown in Table 4,of all the patients whose PSA ranged within the low prostate cancer 
detection levels of 0-2.4ng/dl, 54% had BPH and 15.4% were found to be having cancer 
prostate.Of those whose PSA was considered high (≥4ng/dl), 32% had BPH and 42% had cancer 
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Table 3. PSA, Prostate Volume and Histological findings 
    
Cancer 
Detection 




volume Age Group 
Cancer Detection 
rate of PSA 
Pearson Correlation 1 .097 .275(**) .240(**) 
Sig. (2-tailed)  
(P value) 
  .265 .002 .005 
N 135 133 120 133 
Histology findings Pearson Correlation .097 1 .074 -.188(*) 
Sig. (2-tailed)  
(P value) 
.265   .424 .031 
N 133 133 118 131 
Prostate volume Pearson Correlation .275(**) .074 1 .176 
Sig. (2-tailed) 
(P value) 
.002 .424   .054 
N 120 118 120 120 
Age Group Pearson Correlation .240(**) -.188(*) .176 1 
Sig. (2-tailed) 
(P value) 
.005 .031 .054   
N 133 131 120 133 
 
 




Table 4          Cancer Detection rate of PSA and Histology findings  
Cancer 
Detection 
rate of PSA 
  
Histology findings Total 
BPH Adeno- 
carcinoma 
















































































In this study, Approximate 135 patients were evaluated in the study. The youngest person was 
33years and the oldest was 98years, Mean age 68.5year (SD+/- 13years) Fig 1. Significantly, 
elderly persons constituted 64.5%, compared with Adult who made up to 34.5% and 
approximately 1% was a youth (P=0.00). Other authors have reported similar mean age,and 
that prostate volume increase with age17.  This is because as one ages, the prostate also tend to 
enlarge as a result of decrease in their androgen hormone level. Older Age at biopsy can be 
predictive of the disease8.  PSA measurements before age 50years has been reported to help 
risk-stratify men for intensity of Prostate Cancer screening19.  
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Most patients presented with retention of urine (30%), dribbling of urine (23%), hesitancy 
(16%) and dysuria (13%) and this observed difference was significant P=0.00 (Table 1). On 
examination, 80% of the patients had clinical evidence of BPH and cancer prostate was 13%. 
(P=0.00). However, of the patient who were clinically diagnosed with BPH, 46% correlated well 
with the histological finding While for those diagnosed with clinical caner prostate, 72% were 
found to have a positive histology findings, (P= 0.04). Therefore clinical evaluation is 
emphasized besides PSA because when taken together with a man’s age, family history, 
ethnicity, and digital rectal exam results, PSA levels add to the overall estimate of the risk of 
cancer19and abnormal DRE result and older age at biopsy are often predictive for high-grade 
prostate cancer8.  
According to Figure 2, of the 135 patients, the serum total PSA ranged from 0.1ng/ml to 
88.7ng/ml with average of 15.6ng/ml. When the serum PSA was classified into Low (0.1-
2.4ng/ml), Moderate (2.5-3.9ng/ml) and High 4ng/ml and above, we found the 60.7% of the 
patients had high PSA while 9.6% had moderate and low was 29.6%, (P value=0.00). Young et 
al6 (2011) had earlier classified the cancer detection level of PSA as below 2.5ng/ml, from 2.5 to 
4.0ng/ml, and above 4.0ng/ml, as 13.3%, 13.6% and 26.5%, respectively6. Therefore when PSA 
is taken for all patients with enlarged prostate, a significant proportion of patients tend to have 
a high PSA P=0.000 (Fig 2). Most other studies on PSA analysis have used a cut-off level of 
4ng/ml, and they have reported high cancer detection rate if PSA is more than 4ng/ml 6,20,21. 
As shown in Table 2, Histological examination of prostate biopsy revealed BPH (39%), Cancer 
prostate (33%), inflammation of prostate (15%) and intraepithelial neoplasms (12%). These 
observed difference in histology finding significant is (P=0.00). These finding contrast with the 
findings of those who biopsied the prostate only if the PSA was more than 4ng/ml. For example 
the finding of prostate cancer prevalence of 20.9%, benign prostatic hypertrophy of 4.7%, 
prostatitis of 74.4% by Young et al6 (2011)suggest a low cancer detection rate by limiting 
biopsy to a PSA cut-off of 4ng/ml yet that is an unreliable cut off 8,9.This finding suggests that we 
should biopsy all clinically symptomatic enlarged prostate.  
Table 3 shows a positive correlation ship between PSA and patients age (r= 0.24, P=0.005). 
Therefore as age advances, PSA also tends to increase and most of the elderly persons have PSA 
≥4ng/ml.This finding in our study is also similar to the report of Ornsteinet al7 (1998) that PSA 
levels correlated significantly with age7. Collins etal17 (2008) also found an independent 
association between PSA and age when controlled for volume17.  Liu, Wang,  Su, et al20 (2013) 
found that males with a baseline PSA 3–3.99 ng ml−1 have a 57.81% chance, that their PSA 
would increase above 4.0 ng ml−1 over the following 4 years (P<0.0001)20, thus emphasizing how 
advancing age correlate with PSA increase. Furthermore it was established that Serum PSA 
levels show an exponential increase with advancing age21.However PSA value of ≥4ng/ml is 
suspicious and must be biopsied8. Other authors independently reported that PSA concentration 
in men with a prostate volume <25 cc also showed a continuous increase with aging22. 
Although our study found a mean prostate volume 78.8mls and others reported a lower value 
32 mls17which may be attributable to our poor health seeking behavior, the study found that 
Prostates volume correlates positively with serum PSA, Pearson’s Correlation r=0.275 and P= 
0.002. In 1998, Ornstein et al7, reported prostate volume as being significant predictors PSA. 
The positive relation between PSA and prostate volume was also reported independently by 
many other authors15,19,22,23. Furthermore the study also found that prostate volume also 
correlates with increasing age (Pearson’s correlation r= 0.176 and P= 0.054. Collins, Lee, 
Mckelvieet al21 2008 got a similar finding just as Berges, and Oelke22 in 2011 and Mettlin, 
Littrup, Kane et al24 (2006) also got a similar findings.  
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There is a weak relationship between PSA level and Histological diagnosis, (Pearson’s 
correlation r=0.1, table 3 and table 4 (Chi square 13.561, P= 0.33). This can be attributed to the 
fact the PSA is unreliable and controversial when used in diagnosis of cancer prostate and can 
be misleading if entirely relied upon8,9,10,11,12,14,19, 23, 25,26. 
Conclusion 
Age and prostate volume significantly correlate with serum PSA and age and prostate volume 
also correlates significantly. Since PSA correlates weakly with histological findings, it should 
therefore be used in in-conjunction with other clinico-biographic parameters to diagnose cancer 
prostate.   
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